Molecular pathogenesis of neuromyelitis optica

International Journal of Molecular Sciences

Volumn 13, Issue 10, 2012, Pages 12970-12993

  Bukhari, Wajih ^a,b   Barnett, Michael H ^c   Prain, Kerri ^d   Broadley, Simon A ^a,b  

^a GRIFFITH UNIVERSITY   (Australia)

^b GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Autoimmune laboratory   (Australia)

Author keywords

Aquaporin 4; Astrocyte; Astrocytopathy; Devic's disease; Genetics; Immunology; Multiple sclerosis; Neuromyelitis optica; Pathogenesis

Indexed keywords

AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; IMMUNOGLOBULIN G; RITUXIMAB; AUTOANTIBODY; CYTOKINE; HLA ANTIGEN;

AUTOIMMUNITY; DEMYELINATION; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; MOLECULAR PATHOLOGY; MYELOOPTIC NEUROPATHY; NONHUMAN; REVIEW; RISK FACTOR; SEX DIFFERENCE; ANIMAL; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; TH17 CELL;

ANIMALS; AQUAPORIN 4; AUTOANTIBODIES; CYTOKINES; HLA ANTIGENS; HUMANS; NEUROMYELITIS OPTICA; POLYMORPHISM, GENETIC; TH17 CELLS;

EID: 84867766691     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131012970     Document Type: Review

References (156)

1. Allbutt, T. On the opthalmoscopic signs of spinal disease. Lancet 1870, 1, 76-78.
2. Erb, W. About the concurrence of optic neuritis and subacute myelitis. Arch. Psychiatr. Nervenkr. 1879, 1, 146-157.
3. Jarius, S.; Wildemann, B. On the contribution of thomas clifford allbutt, F.R.S., to the early history of neuromyelitis optica. J. Neurol. 2012, doi:10.1007/s00415-012-6594-3.
4. Devic, E. Myélite subaiguë compliquée de névrite optique. Bull. Med. (Paris) 1894, 8, 1033-1034.
5. Totsuka, S. Clinico-pathological studies on the two cases of neuromyelitis optica (Devic's disease) with a chronic clinical course, with especial reference on its relationship to multiple sclerosis. Folia Psychiatr. Neurol. Jpn. 1962, 64, 1149-1165.
6. Wingerchuk, D.M.; Hogancamp, W.F.; O'Brien, P.C.; Weinshenker, B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53, 1107-1114.
7. Lennon, V.A.; Wingerchuk, D.M.; Kryzer, T.J.; Pittock, S.J.; Lucchinetti, C.F.; Fujihara, K.; Nakashima, I.; Weinshenker, B.G. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004, 364, 2106-2112.
8. Kim, J.S.; Park, Y.H.; Kim, S.M.; Kim, S.H.; Park, K.S.; Sung, J.J.; Lee, K.W. A case of chronic progressive myelopathy. Mult. Scler. 2010, 16, 1255-1257.
9. Wingerchuk, D.M.; Pittock, S.J.; Lucchinetti, C.F.; Lennon, V.A.; Weinshenker, B.G. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007, 68, 603-605.
10. Jarius, S.; Ruprecht, K.; Wildemann, B.; Kuempfel, T.; Ringelstein, M.; Geis, C.; Kleiter, I.; Kleinschnitz, C.; Berthele, A.; Brettschneider, J., et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J. Neuroinflamm. 2012, 9, 14.
11. Jarius, S.; Paul, F.; Franciotta, D.; Ruprecht, K.; Ringelstein, M.; Bergamaschi, R.; Rommer, P.; Kleiter, I.; Stich, O.; Reuss, R., et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures. J. Neurol. Sci. 2011, 306, 82-90.
12. Pittock, S.J.; Lennon, V.A.; Krecke, K.; Wingerchuk, D.M.; Lucchinetti, C.F.; Weinshenker, B.G. Brain abnormalities in neuromyelitis optica. Arch. Neurol. 2006, 63, 390-396.
13. Wingerchuk, D.M.; Lennon, V.A.; Pittock, S.J.; Lucchinetti, C.F.; Weinshenker, B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66, 1485-1489.
14. Wingerchuk, D.M.; Lennon, V.A.; Lucchinetti, C.F.; Pittock, S.J.; Weinshenker, B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6, 805-815.
15. Bizzoco, E.; Lolli, F.; Repice, A.M.; Hakiki, B.; Falcini, M.; Barilaro, A.; Taiuti, R.; Siracusa, G.; Amato, M.P.; Biagioli, T., et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J. Neurol. 2009, 256, 1891-1898.
16. McKeon, A.; Lennon, V.A.; Lotze, T.; Tenenbaum, S.; Ness, J.M.; Rensel, M.; Kuntz, N.L.; Fryer, J.P.; Homburger, H.; Hunter, J., et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008, 71, 93-100.
17. Takahashi, T.; Miyazawa, I.; Misu, T.; Takano, R.; Nakashima, I.; Fujihara, K.; Tobita, M.; Itoyama, Y. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: A herald of acute exacerbations. J. Neurol. Neurosurg. Psychiatry 2008, 79, 1075-1078.
18. Pittock, S.J.; Weinshenker, B.G.; Lucchinetti, C.F.; Wingerchuk, D.M.; Corboy, J.R.; Lennon, V.A. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch. Neurol. 2006, 63, 964-968.
19. Makino, T.; Ito, S.; Mori, M.; Yonezu, T.; Ogawa, Y.; Kuwabara, S. Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica. Mult. Scler. 2012, doi:10.1177/1352458512454772.
20. Ikeda, K.; Ito, H.; Hidaka, T.; Takazawa, T.; Sekine, T.; Yoshii, Y.; Hirayama, T.; Kawabe, K.; Kano, O.; Iwasaki, Y. Repeated non-enhancing tumefactive lesions in a patient with a neuromyelitis optica spectrum disorder. Intern. Med. 2011, 50, 1061-1064.
21. Newey, C.R.; Bermel, R.A. Fulminant cerebral demyelination in neuromyelitis optica. Neurology 2011, 77, 193.
22. Orton, S.M.; Herrera, B.M.; Yee, I.M.; Valdar, W.; Ramagopalan, S.V.; Sadovnick, A.D.; Ebers, G.C.; Canadian Collaborative Study, G. Sex ratio of multiple sclerosis in canada: A longitudinal study. Lancet Neurol. 2006, 5, 932-936.
23. Wingerchuk, D.M.; Weinshenker, B.G. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult. Scler. 2012, 18, 5-10.
24. Wynn, D.R.; Rodriguez, M.; O'Fallon, W.M.; Kurland, L.T. A reappraisal of the epidemiology of multiple sclerosis in Olmsted county, Minnesota. Neurology 1990, 40, 780-786.
25. Broadley, S.A.; Deans, J.; Sawcer, S.J.; Clayton, D.; Compston, D.A. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 2000, 123, 1102-1111.
26. Spadaro, M.; Amendolea, M.A.; Mazzucconi, M.G.; Fantozzi, R.; Di Lello, R.; Zangari, P.; Masala, G. Autoimmunity in multiple sclerosis: Study of a wide spectrum of autoantibodies. Mult. Scler. 1999, 5, 121-125.
27. Henderson, R.D.; Bain, C.J.; Pender, M.P. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J. Clin. Neurosci. 2000, 7, 434-437.
28. Kim, S.H.; Kim, W.; Li, X.F.; Jung, I.J.; Kim, H.J. Does interferon β treatment exacerbate neuromyelitis optica spectrum disorder? Mult. Scler. 2012, doi:10.1177/1352458512439439.
29. Shimizu, J.; Hatanaka, Y.; Hasegawa, M.; Iwata, A.; Sugimoto, I.; Date, H.; Goto, J.; Shimizu, T.; Takatsu, M.; Sakurai, Y., et al. IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010, 75, 1423-1427.
30. Palace, J.; Leite, M.I.; Nairne, A.; Vincent, A. Interferon beta treatment in neuromyelitis optica: Increase in relapses and aquaporin 4 antibody titers. Arch. Neurol. 2010, 67, 1016-1017.
31. Watanabe, S.; Nakashima, I.; Misu, T.; Miyazawa, I.; Shiga, Y.; Fujihara, K.; Itoyama, Y. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult. Scler. 2007, 13, 128-132.
32. Papeix, C.; Vidal, J.S.; de Seze, J.; Pierrot-Deseilligny, C.; Tourbah, A.; Stankoff, B.; Lebrun, C.; Moreau, T.; Vermersch, P.; Fontaine, B., et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult. Scler. 2007, 13, 256-259.
33. Jacob, A.; Weinshenker, B.G.; Violich, I.; McLinskey, N.; Krupp, L.; Fox, R.J.; Wingerchuk, D.M.; Boggild, M.; Constantinescu, C.S.; Miller, A., et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch. Neurol. 2008, 65, 1443-1448.
34. Kim, S.H.; Kim, W.; Li, X.F.; Jung, I.J.; Kim, H.J. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch. Neurol. 2011, 68, 1412-1420.
35. Saadoun, S.; Waters, P.; Bell, B.A.; Vincent, A.; Verkman, A.S.; Papadopoulos, M.C. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010, 133, 349-361.
36. Parratt, J.D.; Prineas, J.W. Neuromyelitis optica: A demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult. Scler. 2010, 16, 1156-1172.
37. Misu, T.; Fujihara, K.; Kakita, A.; Konno, H.; Nakamura, M.; Watanabe, S.; Takahashi, T.; Nakashima, I.; Takahashi, H.; Itoyama, Y. Loss of aquaporin 4 in lesions of neuromyelitis optica: Distinction from multiple sclerosis. Brain 2007, 130, 1224-1234.
38. Preston, G.M.; Carroll, T.P.; Guggino, W.B.; Agre, P. Appearance of water channels in xenopus oocytes expressing red cell CHIP28 protein. Science 1992, 256, 385-387.
39. Verkman, A.S. More than just water channels: Unexpected cellular roles of aquaporins. J. Cell Sci. 2005, 118, 3225-3232.
40. Nielsen, S.; Nagelhus, E.A.; Amiry-Moghaddam, M.; Bourque, C.; Agre, P.; Ottersen, O.P. Specialized membrane domains for water transport in glial cells: High-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J. Neurosci. 1997, 17, 171-180.
41. Frigeri, A.; Gropper, M.A.; Umenishi, F.; Kawashima, M.; Brown, D.; Verkman, A.S. Localization of MIWC and GLIP water channel homologs in neuromuscular, epithelial and glandular tissues. J. Cell Sci. 1995, 108, 2993-3002.
42. Li, J.; Patil, R.V.; Verkman, A.S. Mildly abnormal retinal function in transgenic mice without muller cell aquaporin-4 water channels. Invest. Ophth. Vis. Sci. 2002, 43, 573-579.
43. Venero, J.L.; Vizuete, M.L.; Ilundain, A.A.; Machado, A.; Echevarria, M.; Cano, J. Detailed localization of aquaporin-4 messenger RNA in the CNS: Preferential expression in periventricular organs. Neuroscience 1999, 94, 239-250.
44. Agre, P.; King, L.S.; Yasui, M.; Guggino, W.B.; Ottersen, O.P.; Fujiyoshi, Y.; Engel, A.; Nielsen, S. Aquaporin water channels-From atomic structure to clinical medicine. J. Physiol. 2002, 542, 3-16.
45. Lu, M.Q.; Lee, M.D.; Smith, B.L.; Jung, J.S.; Agre, P.; Verdijk, M.A.J.; Merkx, G.; Rijs, J.P.L.; Deen, P.M.T. The human AQP4 gene: Definition of the locus encoding two water channel polypeptides in brain. Proc. Natl. Acad. Sci. USA 1996, 93, 10908-10912.
46. Neely, J.D.; Christensen, B.M.; Nielsen, S.; Agre, P. Heterotetrameric composition of aquaporin-4 water channels. Biochemistry 1999, 38, 11156-11163.
47. Furman, C.S.; Gorelick-Feldman, D.A.; Davidson, K.G.; Yasumura, T.; Neely, J.D.; Agre, P.; Rash, J.E. Aquaporin-4 square array assembly: Opposing actions of M1 and M23 isoforms. Proc. Natl. Acad. Sci. USA 2003, 100, 13609-13614.
48. Strand, L.; Moe, S.E.; Solbu, T.T.; Vaadal, M.; Holen, T. Roles of aquaporin-4 isoforms and amino acids in square array assembly. Biochemistry 2009, 48, 5785-5793.
49. Suzuki, H.; Nishikawa, K.; Hiroaki, Y.; Fujiyoshi, Y. Formation of aquaporin-4 arrays is inhibited by palmitoylation of N-terminal cysteine residues. BBA-Biomembranes 2008, 1778, 1181-1189.
50. Hinson, S.R.; Roemer, S.F.; Lucchinetti, C.F.; Fryer, J.P.; Kryzer, T.J.; Chamberlain, J.L.; Howe, C.L.; Pittock, S.J.; Lennon, V.A. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J. Exp. Med. 2008, 205, 2473-2481.
51. Marignier, R.; Nicolle, A.; Watrin, C.; Touret, M.; Cavagna, S.; Varrin-Doyer, M.; Cavillon, G.; Rogemond, V.; Confavreux, C.; Honnorat, J., et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 2010, 133, 2578-2591.
52. Ratelade, J.; Bennett, J.L.; Verkman, A.S. Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J. Biol. Chem. 2011, 286, 45156-45164.
53. Manley, G.T.; Fujimura, M.; Ma, T.; Noshita, N.; Filiz, F.; Bollen, A.W.; Chan, P.; Verkman, A.S. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat. Med. 2000, 6, 159-163.
54. Saadoun, S.; Papadopoulos, M.C.; Watanabe, H.; Yan, D.; Manley, G.T.; Verkman, A.S. Involvement of aquaporin-4 in astroglial cell migration and glial scar formation. J. Cell Sci. 2005, 118, 5691-5698.
55. Papadopoulos, M.C.; Manley, G.T.; Krishna, S.; Verkman, A.S. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 2004, 18, 1291-1293.
56. Bloch, O.; Papadopoulos, M.C.; Manley, G.T.; Verkman, A.S. Aquaporin-4 gene deletion in mice increases focal edema associated with staphylococcal brain abscess. J. Neurochem. 2005, 95, 254-262.
57. Waters, P.; Leite, M.I.; Gray, B.; Vincent, A.; Jiang, Y.; Palace, J. Aquaporin-4 M23 isoform provides a more sensitive assay for aquaporin-4 antibodies. J. Neurol. Neurosurg. Psychiatry 2010, 81, E32.
58. Ketelslegers, I.A.; Modderman, P.W.; Vennegoor, A.; Killestein, J.; Hamann, D.; Hintzen, R.Q. Antibodies against aquaporin-4 in neuromyelitis optica: Distinction between recurrent and monophasic patients. Mult. Scler. 2011, 17, 1527-1530.
59. Jarius, S.; Wildemann, B. AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance. Nat. Rev. Neurol. 2010, 6, 383-392.
60. Kira, J. Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: Astrocytopathy as a common denominator in demyelinating disorders. J. Neurol. Sci. 2011, 311, 69-77.
61. Hinson, S.R.; Pittock, S.J.; Lucchinetti, C.F.; Roemer, S.F.; Fryer, J.P.; Kryzer, T.J.; Lennon, V.A. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69, 2221-2231.
62. Jarius, S.; Franciotta, D.; Bergamaschi, R.; Wildemann, B.; Wandinger, K.P. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin. Chem. Lab. Med. 2010, 48, 659-663.
63. Tani, T.; Sakimura, K.; Tsujita, M.; Nakada, T.; Tanaka, M.; Nishizawa, M.; Tanaka, K. Identification of binding sites for anti-aquaporin 4 antibodies in patients with neuromyelitis optica. J. Neuroimmunol. 2009, 211, 110-113.
64. Crane, J.M.; Lam, C.; Rossi, A.; Gupta, T.; Bennett, J.L.; Verkman, A.S. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1/M23 isoforms and orthogonal arrays. J. Biol. Chem. 2011, 286, 16516-16524.
65. Nicchia, G.P.; Mastrototaro, M.; Rossi, A.; Pisani, F.; Tortorella, C.; Ruggieri, M.; Lia, A.; Trojano, M.; Frigeri, A.; Svelto, M. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 2009, 57, 1363-1373.
66. Bradl, M.; Misu, T.; Takahashi, T.; Watanabe, M.; Mader, S.; Reindl, M.; Adzemovic, M.; Bauer, J.; Berger, T.; Fujihara, K., et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 2009, 66, 630-643.
67. Ratelade, J.; Bennett, J.L.; Verkman, A.S. Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS One 2011, 6, e27412.
68. Takahashi, T.; Fujihara, K.; Nakashima, I.; Misu, T.; Miyazawa, I.; Nakamura, M.; Watanabe, S.; Shiga, Y.; Kanaoka, C.; Fujimori, J., et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain 2007, 130, 1235-1243.
69. Kalluri, S.R.; Illes, Z.; Srivastava, R.; Cree, B.; Menge, T.; Bennett, J.L.; Berthele, A.; Hemmer, B. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch. Neurol. 2010, 67, 1201-1208.
70. Klawiter, E.C.; Alvarez, E., 3rd; Xu, J.; Paciorkowski, A.R.; Zhu, L.; Parks, B.J.; Cross, A.H.; Naismith, R.T. NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology 2009, 72, 1101-1103.
71. Bennett, J.L.; Lam, C.; Kalluri, S.R.; Saikali, P.; Bautista, K.; Dupree, C.; Glogowska, M.; Case, D.; Antel, J.P.; Owens, G.P., et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 2009, 66, 617-629.
72. Chihara, N.; Aranami, T.; Sato, W.; Miyazaki, Y.; Miyake, S.; Okamoto, T.; Ogawa, M.; Toda, T.; Yamamura, T. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc. Natl. Acad. Sci. USA 2011, 108, 3701-3706.
73. Kira, J. Multiple sclerosis in the japanese population. Lancet Neurol. 2003, 2, 117-127.
74. Osuntokun, B.O. The pattern of neurological illness in tropical Africa. Experience at Ibadan, Nigeria. J. Neurol. Sci. 1971, 12, 417-442.
75. Chopra, J.S.; Radhakrishnan, K.; Sawhney, B.B.; Pal, S.R.; Banerjee, A.K. Multiple sclerosis in north-west India. Acta Neurol. Scand. 1980, 62, 312-321.
76. Papais-Alvarenga, R.M.; Miranda-Santos, C.M.; Puccioni-Sohler, M.; de Almeida, A.M.; Oliveira, S.; Basilio De Oliveira, C.A.; Alvarenga, H.; Poser, C.M. Optic neuromyelitis syndrome in Brazilian patients. J. Neurol. Neurosurg. Psychiatry 2002, 73, 429-435.
77. McAlpine, D. Familial neuromyelitis optica: Its occurrence in identical twins. Brain 1938, 61, 430-448.
78. Matiello, M.; Kim, H.J.; Kim, W.; Brum, D.G.; Barreira, A.A.; Kingsbury, D.J.; Plant, G.T.; Adoni, T.; Weinshenker, B.G. Familial neuromyelitis optica. Neurology 2010, 75, 310-315.
79. Zephir, H.; Fajardy, I.; Outteryck, O.; Blanc, F.; Roger, N.; Fleury, M.; Rudolf, G.; Marignier, R.; Vukusic, S.; Confavreux, C., et al. Is neuromyelitis optica associated with human leukocyte antigen? Mult. Scler. 2009, 15, 571-579.
80. Brum, D.G.; Barreira, A.A.; dos Santos, A.C.; Kaimen-Maciel, D.R.; Matiello, M.; Costa, R.M.; Deghaide, N.H.; Costa, L.S.; Louzada-Junior, P.; Diniz, P.R., et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult. Scler. 2010, 16, 21-29.
81. Matsushita, T.; Matsuoka, T.; Isobe, N.; Kawano, Y.; Minohara, M.; Shi, N.; Nishimura, Y.; Ochi, H.; Kira, J. Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens 2009, 73, 171-176.
82. Wang, H.; Dai, Y.; Qiu, W.; Zhong, X.; Wu, A.; Wang, Y.; Lu, Z.; Bao, J.; Hu, X. HLA-DPB1 0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in southern han chinese. J. Neuroimmunol. 2011, 233, 181-184.
83. Tsao, B.P. The genetics of human systemic lupus erythematosus. Trends Immunol. 2003, 24, 595-602.
84. Onuma, H.; Ota, M.; Sugenoya, A.; Inoko, H. Association of HLA-DPB1*0501 with early-onset Graves' disease in Japanese. Hum. Immunol. 1994, 39, 195-201.
85. Matiello, M.; Kantarci, O.; Brum, D.; Schaefer-Klein, J.; Weinshenker, B.; Consortium, N.G. HLA DRB1*1501 tagging rs3135388 polymorphism associated with multiple sclerosis is inversely associated with NMO. Mult. Scler. 2009, 15, S69.
86. Deschamps, R.; Paturel, L.; Jeannin, S.; Chausson, N.; Olindo, S.; Bera, O.; Bellance, R.; Smadja, D.; Cesaire, D.; Cabre, P. Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to nmo and multiple sclerosis among the French Afro-Caribbean population. Mult. Scler. 2011, 17, 24-31.
87. Stewart, G.J.; Teutsch, S.M.; Castle, M.; Heard, R.N.; Bennetts, B.H. HLA-DR, -DQA1 and -DQB1 associations in Australian multiple sclerosis patients. Eur. J. Immunogenet. 1997, 24, 81-92.
88. Mealy, M.A.; Wingerchuk, D.M.; Greenberg, B.M.; Levy, M. Epidemiology of neuromyelitis optica in the United States: A multicenter analysis epidemiology of NMO. Arch. Neurol. 2012, 69, 1176-1180.
89. Matiello, M.; Schaefer-Klein, J.L.; Hebrink, D.D.; Kingsbury, D.J.; Atkinson, E.J.; Weinshenker, B.G. NMO genetics collaborators, genetic analysis of aquaporin-4 in neuromyelitis optica. Neurology 2011, 77, 1149-1155.
90. Rossi, A.; Pisani, F.; Nicchia, G.P.; Svelto, M.; Frigeri, A. Evidences for a leaky scanning mechanism for the synthesis of the shorter M23 protein isoform of aquaporin-4 implication in orthogonal array formation and neuromyelitis optica antibody interaction. J. Biol. Chem. 2010, 285, 4562-4569.
91. Sellner, J.; Hemmer, B.; Muhlau, M. The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (devic) syndromes. J. Autoimmunity 2010, 34, 371-379.
92. Menge, T.; Cree, B.; Saleh, A.; Waterboer, T.; Berthele, A.; Kalluri, S.R.; Hemmer, B.; Aktas, O.; Hartung, H.P.; Methner, A., et al. Neuromyelitis optica following human papillomavirus vaccination. Neurology 2012, 79, 285-287.
93. Pittock, S.J.; Lennon, V.A. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch. Neurol. 2008, 65, 629-632.
94. Varrin-Doyer, M.; Spencer, C.M.; Schulze-Topphoff, U.; Nelson, P.A.; Stroud, R.M.; BA, C.C.; Zamvil, S.S. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann. Neurol. 2012, 72, 53-64.
95. Hatheway, C.L. Toxigenic clostridia. Clin. Microbiol. Rev. 1990, 3, 66-98.
96. Egg, R.; Reindl, M.; Deisenhammer, F.; Linington, C.; Berger, T. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult. Scler. 2001, 7, 285-289.
97. Angelucci, F.; Mirabella, M.; Frisullo, G.; Caggiula, M.; Tonali, P.A.; Batocchi, A.P. Serum levels of anti-myelin antibodies in relapsing-remitting multiple sclerosis patients during different phases of disease activity and immunomodulatory therapy. Dis. Markers 2005, 21, 49-55.
98. Li, L.; Zhang, H.; Varrin-Doyer, M.; Zamvil, S.S.; Verkman, A.S. Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. FASEB J. 2011, 25, 1556-1566.
99. Kinoshita, M.; Nakatsuji, Y.; Kimura, T.; Moriya, M.; Takata, K.; Okuno, T.; Kumanogoh, A.; Kajiyama, K.; Yoshikawa, H.; Sakoda, S. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem. Biophys. Res. Commun. 2009, 386, 623-627.
100. Zhang, H.; Bennett, J.L.; Verkman, A.S. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann. Neurol. 2011, 70, 943-954.
101. Kinoshita, M.; Nakatsuji, Y.; Kimura, T.; Moriya, M.; Takata, K.; Okuno, T.; Kumanogoh, A.; Kajiyama, K.; Yoshikawa, H.; Sakoda, S. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem. Biophys. Res. Commun. 2010, 394, 205-210.
102. Lennon, V.A.; Kryzer, T.J.; Pittock, S.J.; Verkman, A.S.; Hinson, S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005, 202, 473-477.
103. Jarius, S.; Aboul-Enein, F.; Waters, P.; Kuenz, B.; Hauser, A.; Berger, T.; Lang, W.; Reindl, M.; Vincent, A.; Kristoferitsch, W. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008, 131, 3072-3080.
104. Hinson, S.R.; McKeon, A.; Fryer, J.P.; Apiwattanakul, M.; Lennon, V.A.; Pittock, S.J. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch. Neurol. 2009, 66, 1164-1167.
105. Matsushita, T.; Isobe, N.; Matsuoka, T.; Shi, N.; Kawano, Y.; Wu, X.M.; Yoshiura, T.; Nakao, Y.; Ishizu, T.; Kira, J.I. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese. Mult. Scler. 2009, 15, 834-847.
106. Nishiyama, S.; Ito, T.; Misu, T.; Takahashi, T.; Kikuchi, A.; Suzuki, N.; Jin, K.; Aoki, M.; Fujihara, K.; Itoyama, Y. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 2009, 72, 1960-1961.
107. Kinoshita, M.; Nakatsuji, Y.; Moriya, M.; Okuno, T.; Kumanogoh, A.; Nakano, M.; Takahashi, T.; Fujihara, K.; Tanaka, K.; Sakoda, S. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 2009, 20, 508-512.
108. Kim, Y.U.; Kinoshita, T.; Molina, H.; Hourcade, D.; Seya, T.; Wagner, L.M.; Holers, V.M. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J. Exp. Med. 1995, 181, 151-159.
109. Lener, M.; Vinci, G.; Duponchel, C.; Meo, T.; Tosi, M. Molecular cloning, gene structure and expression profile of mouse C1 inhibitor. Eur. J. Biochem. 1998, 254, 117-122.
110. Pinter, C.; Beltrami, S.; Caputo, D.; Ferrante, P.; Clivio, A. Presence of autoantibodies against complement regulatory proteins in relapsing-remitting multiple sclerosis. J. Neurovirol. 2000, 6, S42-S46.
111. Vincent, T.; Saikali, P.; Cayrol, R.; Roth, A.D.; Bar-Or, A.; Prat, A.; Antel, J.P. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J. Immunol. 2008, 181, 5730-5737.
112. Hinson, S.R.; Romero, M.F.; Popescu, B.F.; Lucchinetti, C.F.; Fryer, J.P.; Wolburg, H.; Fallier-Becker, P.; Noell, S.; Lennon, V.A. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc. Natl. Acad. Sci. USA 2012, 109, 1245-1250.
113. Melamud, L.; Fernandez, J.M.; Rivarola, V.; Di Giusto, G.; Ford, P.; Villa, A.; Capurro, C. Neuromyelitis optica immunoglobulin G present in sera from neuromyelitis optica patients affects aquaporin-4 expression and water permeability of the astrocyte plasma membrane. J. Neurosci. Res. 2012, 90, 1240-1248.
114. Rossi, A.; Ratelade, J.; Papadopoulos, M.C.; Bennett, J.L.; Verkman, A.S. Consequences of NMO-IgG binding to aquaporin-4 in neuromyelitis optica. Proc. Natl. Acad. Sci. USA 2012, 109, doi:10.1073/pnas.1203463109.
115. Eng, L.F.; Ghirnikar, R.S.; Lee, Y.L. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem. Res. 2000, 25, 1439-1451.
116. Takano, R.; Misu, T.; Takahashi, T.; Sato, S.; Fujihara, K.; Itoyama, Y. Astrocytic damage is far more severe than demyelination in NMO a clinical CSF biomarker study. Neurology 2010, 75, 208-216.
117. Sofroniew, M.V.; Vinters, H.V. Astrocytes: Biology and pathology. Acta Neuropathol. 2010, 119, 7-35.
118. Uzawa, A.; Mori, M.; Arai, K.; Sato, Y.; Hayakawa, S.; Masuda, S.; Taniguchi, J.; Kuwabara, S. Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6. Mult. Scler. 2010, 16, 1443-1452.
119. Tanaka, M.; Matsushita, T.; Tateishi, T.; Ochi, H.; Kawano, Y.; Mei, F.J.; Minohara, M.; Murai, H.; Kira, J.I. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 2008, 71, 974-981.
120. Ishizu, T.; Osoegawa, M.; Mei, F.J.; Kikuchi, H.; Tanaka, M.; Takakura, Y.; Minohara, M.; Murai, H.; Mihara, F.; Taniwaki, T., et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005, 128, 988-1002.
121. Correale, J.; Fiol, M. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis. Mult. Scler. 2011, 17, 521-531.
122. Mandler, R.N.; Davis, L.E.; Jeffery, D.R.; Kornfeld, M. Devic's neuromyelitis optica: A clinicopathological study of 8 patients. Ann. Neurol. 1993, 34, 162-168.
123. Zhong, X.; Wang, H.; Dai, Y.; Wu, A.; Bao, J.; Xu, W.; Cheng, C.; Lu, Z.; Qiu, W.; Hu, X. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J. Neuroimmunol. 2011, 240-241, 104-108.
124. Manzo, A.; Vitolo, B.; Humby, F.; Caporali, R.; Jarrossay, D.; Dell'accio, F.; Ciardelli, L.; Uguccioni, M.; Montecucco, C.; Pitzalis, C. Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum. 2008, 58, 3377-3387.
125. Carlsen, H.S.; Baekkevold, E.S.; Morton, H.C.; Haraldsen, G.; Brandtzaeg, P. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood 2004, 104, 3021-3027.
126. Vaknin-Dembinsky, A.; Brill, L.; Orpaz, N.; Abramsky, O.; Karussis, D. Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population. Mult. Scler. 2010, 16, 1453-1457.
127. Mackay, F.; Schneider, P. Cracking the BAFF code. Nat. Rev. Immunol. 2009, 9, 491-502.
128. Krumbholz, M.; Theil, D.; Derfuss, T.; Rosenwald, A.; Schrader, F.; Monoranu, C.M.; Kalled, S.L.; Hess, D.M.; Serafini, B.; Aloisi, F., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 2005, 201, 195-200.
129. Kayagaki, N.; Yan, M.; Seshasayee, D.; Wang, H.; Lee, W.; French, D.M.; Grewal, I.S.; Cochran, A.G.; Gordon, N.C.; Yin, J., et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002, 17, 515-524.
130. Bergamaschi, R. Glatiramer acetate treatment in Devic's neuromyelitis optica. Brain 2003, 126, doi:10.1093/brain/awg140.
131. Gartzen, K.; Limmroth, V.; Putzki, N. Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. Eur. J. Neurol. 2007, 14, e12-e13.
132. Icoz, S.; Tuzun, E.; Kurtuncu, M.; Durmus, H.; Mutlu, M.; Eraksoy, M.; Akman-Demir, G. Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int. J. Neurosci. 2010, 120, 71-75.
133. Farina, C.; Aloisi, F.; Meinl, E. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 2007, 28, 138-145.
134. Ulusoy, C.; Tuzun, E.; Kurtuncu, M.; Turkoglu, R.; Akman-Demir, G.; Eraksoy, M. Comparison of the cytokine profiles of patients with neuronal-antibody-associated central nervous system disorders. Int. J. Neurosci. 2012, 122, 284-289.
135. Bettelli, E.; Carrier, Y.; Gao, W.; Korn, T.; Strom, T.B.; Oukka, M.; Weiner, H.L.; Kuchroo, V.K. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006, 441, 235-238.
136. Wilke, C.M.; Bishop, K.; Fox, D.; Zou, W. Deciphering the role of Th17 cells in human disease. Trends Immunol. 2011, 32, 603-611.
137. Wang, H.H.; Dai, Y.Q.; Qiu, W.; Lu, Z.Q.; Peng, F.H.; Wang, Y.G.; Bao, J.; Li, Y.; Hu, X.Q. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J. Clin. Neurosci. 2011, 18, 1313-1317.
138. Li, Y.; Wang, H.; Long, Y.; Lu, Z.; Hu, X. Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J. Neuroimmunol. 2011, 234, 155-160.
139. Murphy, A.C.; Lalor, S.J.; Lynch, M.A.; Mills, K.H. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav. Immun. 2010, 24, 641-651.
140. Matsuya, N.; Komori, M.; Nomura, K.; Nakane, S.; Fukudome, T.; Goto, H.; Shiraishi, H.; Wandinger, K.P.; Matsuo, H.; Kondo, T. Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. Int. Immunol. 2011, 23, 565-573.
141. Vaknin-Dembinsky, A.; Brill, L.; Kassis, I.; Petrou, P.; Ovadia, H.; Ben-Hur, T.; Abramsky, O.; Karussis, D. T-cell reactivity against AQP4 in neuromyelitis optica. Neurology 2012, 79, 945-946.
142. Nakashima, I.; Takahashi, T.; Cree, B.A.; Kim, H.J.; Suzuki, C.; Genain, C.P.; Vincent, T.; Fujihara, K.; Itoyama, Y.; Bar-Or, A. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J. Clin. Neurosci. 2011, 18, 997-998.
143. Tedder, T.F.; Engel, P. Cd20: A regulator of cell-cycle progression of B lymphocytes. Immunol. Today 1994, 15, 450-454.
144. Manz, R.A.; Arce, S.; Cassese, G.; Hauser, A.E.; Hiepe, F.; Radbruch, A. Humoral immunity and long-lived plasma cells. Curr. Opin. Immunol. 2002, 14, 517-521.
145. Uzawa, A.; Mori, M.; Masuda, S.; Kuwabara, S. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. Arch. Neurol. 2011, 68, 913-917.
146. Shimizu, F.; Sano, Y.; Takahashi, T.; Haruki, H.; Saito, K.; Koga, M.; Kanda, T. Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J. Neurol. Neurosurg. Psychiatry 2012, 83, 288-297.
147. Roemer, S.F.; Parisi, J.E.; Lennon, V.A.; Benarroch, E.E.; Lassmann, H.; Bruck, W.; Mandler, R.N.; Weinshenker, B.G.; Pittock, S.J.; Wingerchuk, D.M., et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130, 1194-1205.
148. Lucchinetti, C.F.; Mandler, R.N.; McGavern, D.; Bruck, W.; Gleich, G.; Ransohoff, R.M.; Trebst, C.; Weinshenker, B.; Wingerchuk, D.; Parisi, J.E., et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125, 1450-1461.
149. Barnett, M.H.; Parratt, J.D.; Cho, E.S.; Prineas, J.W. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann. Neurol. 2009, 65, 32-46.
150. Barnett, M.H.; Prineas, J.W.; Buckland, M.E.; Parratt, J.D.; Pollard, J.D. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult. Scler. 2012, 18, 108-112.
151. Kobayashi, Z.; Tsuchiya, K.; Uchihara, T.; Nakamura, A.; Haga, C.; Yokota, O.; Ishizu, H.; Taki, K.; Arai, T.; Akiyama, H., et al. Intractable hiccup caused by medulla oblongata lesions: A study of an autopsy patient with possible neuromyelitis optica. J. Neurol. Sci. 2009, 285, 241-245.
152. Matsuoka, T.; Suzuki, S.O.; Suenaga, T.; Iwaki, T.; Kira, J. Reappraisal of aquaporin-4 astrocytopathy in asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol. 2011, 21, 516-532.
153. Lee, D.H.; Metz, I.; Berthele, A.; Stadelmann, C.; Bruck, W.; Linker, R.A.; Gold, R.; Schroeder, A. Supraspinal demyelinating lesions in neuromyelitis optica display a typical astrocyte pathology. Neuropathol. Appl. Neurobiol. 2010, 36, 685-687.
154. Tradtrantip, L.; Zhang, H.; Anderson, M.O.; Saadoun, S.; Phuan, P.W.; Papadopoulos, M.C.; Bennett, J.L.; Verkman, A.S. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J. 2012, 26, 2197-2208.
155. Hutas, G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr. Opin. Investig. Drugs 2008, 9, 1206-1215.
156. Herbst, R.; Wang, Y.; Gallagher, S.; Mittereder, N.; Kuta, E.; Damschroder, M.; Woods, R.; Rowe, D.C.; Cheng, L.; Cook, K., et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J. Pharmacol. Exp. Ther. 2010, 335, 213-222.